Amphastar Pharmaceuticals (AMPH) Gross Margin (2013 - 2026)

Amphastar Pharmaceuticals' Gross Margin history runs 14 years deep, the most recent figure standing at 41.08% for Q1 2026.

• On a quarterly basis, Gross Margin fell 891.0% year-over-year to 41.08% in Q1 2026; TTM through Mar 2026 was 47.34%, a 316.0% decrease from a year earlier, with the FY2025 full-year figure at 49.46%, down 162.0% from the prior year.
• Gross Margin fell to 41.08% in Q1 2026 per AMPH's latest filing, from 46.79% in the prior quarter.
• Across five years, Gross Margin topped out at 60.04% in Q3 2023 and bottomed at 41.08% in Q1 2026.
• The 5-year median for Gross Margin is 51.31% (2022), against an average of 50.53%.
• Across the five-year window, Gross Margin soared 1133 bps in 2023 and slumped 891 bps in 2026, its largest moves.
• Year by year, Gross Margin stood at 52.71% in 2022, then grew by 2 bps to 53.98% in 2023, then fell by 14 bps to 46.45% in 2024, then climbed by 1 bps to 46.79% in 2025, then fell by 12 bps to 41.08% in 2026.
• Per Business Quant, the three latest AMPH Gross Margin figures stand at 41.08% (Q1 2026), 46.79% (Q4 2025), and 51.42% (Q3 2025).